Inozyme Pharma to Present at the Jefferies Healthcare Conference
June 02 2023 - 6:30AM
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease
biopharmaceutical company developing novel therapeutics for the
treatment of pathologic mineralization and intimal proliferation,
today announced Douglas A. Treco, Ph.D., the company’s chief
executive officer and chairman of the board, will present at the
Jefferies Healthcare Conference on Friday, June 9, 2023, from
9:30-9:55 a.m. ET.
A live webcast of the presentation can be
accessed from the Investor Relations section of Inozyme’s
website under events, where a replay of the event will also be
available for a limited time.
About Inozyme Pharma
Inozyme Pharma, Inc. (Nasdaq: INZY) is a
clinical-stage rare disease biopharmaceutical company developing
novel therapeutics for the treatment of diseases impacting the
vasculature, soft tissue, and skeleton. We are developing INZ-701,
an enzyme replacement therapy, to address pathologic mineralization
and intimal proliferation which can drive morbidity and mortality
in these severe diseases. INZ-701 is currently in Phase 1/2
clinical trials for the treatment of ENPP1 Deficiency and ABCC6
Deficiency.
For more information, please
visit www.inozyme.com and follow us
on LinkedIn, Twitter, and Facebook.
ContactsInvestors:Inozyme PharmaStefan Riley,
Director of IR and Corporate Communications(857)
330-8871stefan.riley@inozyme.com
Media:SmithSolveMatt Pera(973)
886-9150matt.pera@smithsolve.com
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
From Apr 2024 to May 2024
Inozyme Pharma (NASDAQ:INZY)
Historical Stock Chart
From May 2023 to May 2024